Galapagos Total Assets 2013-2021 | GLPG

Galapagos total assets from 2013 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Galapagos Annual Total Assets
(Millions of US $)
2020 $6,531
2019 $6,797
2018 $1,700
2017 $1,454
2016 $1,199
2015 $491
2014 $360
2013 $382
2012 $303
Galapagos Quarterly Total Assets
(Millions of US $)
2021-09-30 $6,287
2021-06-30 $6,543
2021-03-31 $6,770
2020-12-31 $6,531
2020-09-30 $6,688
2020-06-30 $6,443
2020-03-31 $6,611
2019-12-31 $6,797
2019-09-30 $6,507
2019-06-30 $1,526
2019-03-31 $1,590
2018-12-31 $1,700
2018-09-30 $1,727
2018-06-30 $1,436
2018-03-31 $1,512
2017-03-31 $1,187
2016-03-31 $1,191
2015-12-31 $491
2015-09-30 $513
2015-06-30 $540
2015-03-31 $0
2014-12-31 $360
2014-06-30 $418
2013-12-31 $382
2012-12-31 $303
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.164B $0.606B
Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $122.991B 7.77
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.439B 21.07
Biohaven Pharmaceutical Holding (BHVN) United States $7.159B 0.00
Arcus Biosciences (RCUS) United States $3.161B 0.00
Emergent Biosolutions (EBS) United States $2.298B 8.26
ADC Therapeutics SA (ADCT) Switzerland $1.545B 0.00
Myovant Sciences (MYOV) United Kingdom $1.443B 0.00
Zymeworks (ZYME) Canada $0.942B 0.00
Ambrx Biopharma (AMAM) United States $0.348B 0.00
SQZ Biotechnologies (SQZ) United States $0.329B 0.00
Enzo Biochem (ENZ) United States $0.163B 16.00